Introduction {#Sec1}
============

Fluoroquinolones are among the most commonly prescribed antibiotics, accounting for 23 million and 3.8 million oral and injectable prescriptions in the US in 2011, respectively \[[@CR1], [@CR2]\]. Attractive features of this class include their favorable pharmacokinetic (PK) properties, broad spectrum of activity and clinical efficacy for a wide range of commonly encountered infections \[[@CR3]\]. However, paralleling the widespread use of fluoroquinolones has been an alarming increase in the prevalence of fluoroquinolone resistance among clinically relevant pathogens, underscoring the critical need to consider antimicrobial stewardship principles when defining the place in therapy of novel agents to ensure their utility is not short lived \[[@CR4], [@CR5]\].

Delafloxacin (formerly WQ-3034, ABT492, RX-3341), a novel dual-targeting anionic fluoroquinolone with useful in vitro activity against methicillin-resistant *Staphylococcus aureus* (MRSA), recently received US Food and Drug Administration (FDA) approval for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and is currently being evaluated in a phase 3 trial for the treatment of community-acquired pneumonia (CAP) \[[@CR6]\]. Fluoroquinolones have not traditionally been among the first-line options for ABSSSI; however, delafloxacin's unique structural and chemical characteristics, which result in enhanced potency and intracellular penetration under acidic conditions, suggest it has the potential to fill a distinctive therapeutic niche for certain difficult-to-treat infections \[[@CR7]\]. Furthermore, its dual targeting mechanism may serve to limit the emergence of resistance \[[@CR8]\]. The purpose of this article is to critically review available data pertaining to delafloxacin's biochemistry, pharmacokinetic/pharmacodynamics (PK/PD) characteristics, in vitro activity and potential for resistance selection as well as current progress in clinical trials to ultimately delineate future research priorities and assist clinicians in selecting patients most likely to benefit from the distinctive properties of this agent.

Compliance with Ethics Guidelines {#Sec2}
---------------------------------

This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Data Sources {#Sec3}
------------

Literature searches of MEDLINE (1946 to July 2017) and EMBASE (1974 to July 2017) were conducted using the search terms "ABT-492," "WQ-3034," "RX-3341" and "delafloxacin." Results were limited to articles available in English. Additional citations were identified from the references of relevant literature. Current trials focusing on delafloxacin were identified from clinicaltrials.gov. FDA review documents for the ABSSSI indication were also examined. Lastly, data were obtained from conference proceedings and published abstracts.

Chemistry and Mechanism of Action {#Sec4}
=================================

The fluoroquinolone class of antibiotics exerts antimicrobial activity by inhibiting the two key enzymes, DNA gyrase and topoisomerase IV, which are essential for replication \[[@CR9]\]. Although all fluoroquinolones in clinical use are active against both enzymes, they differ in relative inhibitory potency, with DNA gyrase as the more sensitive target among gram-negative bacteria and topoisomerase IV as the preferential target among gram-positive pathogens \[[@CR9]\]. Delafloxacin demonstrates more balanced activity against both enzymes \[[@CR8]\]. In theory, equipotent enzyme inhibition should serve to limit resistance selection since double mutations are relatively rare genetic events \[[@CR10]\].

Delafloxacin demonstrates minimum inhibitory concentrations (MICs) that are consistently three- to five-fold lower than comparator fluoroquinolones against gram-positive organisms. This is thought to be derived in part from its greater affinity for DNA gyrase compared with other fluoroquinolones. Because DNA gyrase acts ahead of the replication fork to remove positive supercoils, it inhibits DNA replication more rapidly than the interaction with topoisomerase IV, which acts behind it and, as noted, is the preferential target of comparator fluoroquinolones \[[@CR11]\]. Delafoxacin's increased potency against gram-positive bacteria is also related to its specific shape, size and polarity \[[@CR12]\]. Distinguishing structural characteristics include the presence of a sizable substituted heteroaromatic ring at N1, the absence of a basic group at C7 and weak polarity defined by the chlorine atom at C8 (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR12]\]. The heteroaromatic ring at N1 increases the solvent-accessible surface area, and collaboration between this large substituent and the weakly polar group at C8 is thought to influence potency against quinolone-resistant gram-positive bacteria \[[@CR12]\]. It is hypothesized that this C8 substitution could also reduce second-step resistance development in *S. aureus* \[[@CR13], [@CR14]\]. The absence of a basic group at C7 gives delafloxacin an anionic character at neutral pH \[[@CR7]\]. This latter characteristic is unlike the majority of other fluoroquinolones, which exist as zwitterions at physiologic pH \[[@CR7]\]. Under the acidic conditions that characterize the local environment at many infection sites (urinary tract, abscess fluid, decubitis ulcers, epithelial lining fluid and phagolysosomes of infected cells), delafloxacin exists predominantly in the neutral form, which favors uptake by both eukaryotic cells and bacteria \[[@CR7]\]. This is accompanied by increased activity against both extra- and intracellular pathogens, in particular *S. aureus,* and contrasts what has been observed for other agents (fluoroquinolones, macrolides, aminoglycosides), which lose antibacterial potency under acidic conditions \[[@CR7]\]. Delafloxacin MICs against a diverse range of gram-negative and -positive organisms decrease four- to seven-fold as pH in the surrounding media is reduced from 7.2 to 5.5 \[[@CR15]\]. The reduction in MICs are most pronounced among gram-positive bacteria \[[@CR15]\].Fig. 1Chemical structure of delafloxacin

Microbiology {#Sec5}
============

The in vitro activity of delafloxacin and comparator fluoroquinolones against a diverse range of gram-positive and -negative bacteria are presented in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. Minimum inhibitory concentration (MIC~90~, range) values are representative of pooled data from studies conducted with delafloxacin with preference for studies conducted using isolates collected within the last 5 years \[[@CR16], [@CR17]\]. Standard MIC determination methods are conducted under neutral pH conditions, and these values may give a conservative estimate of delafloxacin activity under acidic physiologic conditions.Table 1In vitro activity (MIC, mg/l) of delafloxacin and comparators against aerobic gram-positive bacteria.Adapted from references \[[@CR18]--[@CR20], [@CR23]\]OrganismPhenotypeDelafloxacinLevofloxacinMoxifloxacinMIC~90~RangeMIC~90~RangeMIC~90~Range*Staphylococcus aureus*All0.25≤ 0.004 to 4\> 4≤ 0.12 to \> 4MSSA0.015≤ 0.004 to 42≤ 0.12 to \> 4MRSA0.5≤ 0.004 to 4\>4≤ 0.12 to \> 4Coagulase-negative StaphylococciAll0.5≤ 0.004 to 21≤ 0.12 to \> 4MSCoNS0.03≤ 0.004 to 14≤ 0.12 to \> 4MRCoNS1≤ 0.004 to 2\> 4≤ 0.12 to \> 4*Enterococcus faecalis*All1≤ 0.004 to 2\> 40.25 to \> 4VSE1≤ 0.004 to 2\> 40.25 to \> 4VRE1≤ 0.008 to 2\> 4\> 4*Enterococcus faecium*All\> 40.008 to \> 4\> 40.5 to \> 4VSE\> 40.008 to \> 4\> 4\> 4VRE\> 4\> 4\> 4\> 4*Streptococcus pneumoniae*All0.03≤ 0.004 to 0.2510.5 to \> 40.25≤ 0.12 to 4PSSP0.03≤ 0.004 to 0.0310.5 to 1PISP0.0150.008 to 0.1510.5 to 1PRSP0.030.008 to 0.0310.5 to 10.25≤ 0.12 to 0.25MDR0.015≤ 0.004 to 0.1210.5 to \> 40.25≤ 0.12 to 4Ceftriaxone non-susceptibleNR≤ 0.004 to 0.015NR1 to 2≤ 0.12 to 0.25Levofloxacin resistant0.50.015 to 1322 to 3240.25 to \> 4*Streptococcus pyogenes*0.015≤ 0.004 to 0.0310.25 to \> 40.25≤ 0.12 to 0.5*Streptococcus agalactiae*0.03≤ 0.004 to 0.510.25 to \> 40.25≤ 0.12 to \> 4*Streptococcus dysgalaciae*0.015≤ 0.004 to 0.0310.25 to \> 40.25≤ 0.12 to 0.25Viridans group Streptococci0.06≤ 0.004 to 22≤ 0.12 to \> 40.25≤ 0.12 to 4Streptococcus anignosus group0.0150.008 to 0.0150.50.5Streptococcus mitis group0.060.03 to 0.0621 to 2*Listeria monocytogenes*0.120.06 to 0.1211*MIC* minimum inhibitory concentration, *MRCoNS* methicillin-resistant coagulase-negative staphylococcus, *MRSA* methicillin-resistant *Staphylococcus aureus*, *MSCoNS* methicillin-susceptible coagulase-negative staphylococcus, *MSSA* methicillin-susceptible *Staphylococcus aureus*, *NA* not applicable, *NR* not reported, *PISP* penicillin-intermediate *Streptococcus pneumoniae*, PRSP, penicillin-resistant *Streptococcus pneumoniae*, *PSSP* penicillin-susceptible *Streptococcus pneumoniae*, *VRE* vancomycin-resistant enterococcus, *VSE* vancomycin-susceptible enterococcus Table 2In vitro activity (MIC, mg/l) of delafloxacin and comparators against aerobic gram-negative bacteria.Adapted from references \[[@CR11], [@CR18]--[@CR20], [@CR23], [@CR24]\]OrganismPhenotypeDelafloxacinLevofloxacinCiprofloxacinMIC~90~RangeMIC~90~RangeMIC~90~Range*Escherichia coli*All4≤ 0.004 to \> 4\> 4≤ 0.12 to \> 4\> 4≤ 0.03 to \> 4ESBL\> 40.008 to \> 4\> 4≤ 0.12 to \> 4\> 4≤ 0.03 to \> 4*Klebsiella pneumoniae*All\> 40.015 to \> 4\> 4≤ 0.12 to \> 4ESBL\> 40.06 to \> 4\> 4≤ 0.12 to \> 4*Klebseilla oxytoca*0.120.03 to 1≤ 0.12≤ 0.12 to 10.06≤ 0.03 to \> 4*Proteus mirabilis*All20.015 to \> 4\> 4≤ 0.12 to \> 4\> 4≤ 0.03 to \> 4ESBL\> 42 to \> 4\> 4\> 4*Enterobacter* spp.1≤0.004 to \> 40.5≤ 0.12 to \> 40.25≤ 0.03 to \> 4*Citrobacter* spp.20.008 to \> 40.5≤ 0.12 to \> 40.5≤ 0.03 to \> 4*Serratia* spp.20.03 to \> 41≤ 0.12 to \> 41≤ 0.03 to \> 4*Providencia* spp.0.120.008 to 0.50.250.12 to 0.25*Morganella morganii*40.12 to 4\> 4≤ 0.12 to \> 4*Proteus* spp.Indole-positive40.008 to \> 4\> 4≤ 0.12 to \> 4\> 4≤ 0.03 to \> 4*Salmonella* spp.0.060.008 to 0.50.060.015 to 10.0150.002 to 0.25*Shigella* spp.NR0.002 to 0.008NR0.004 to 0.015*Pseudomonas aeruginosa*\> 40.015 to \> 4\> 4≤ 0.12 to \> 4\>4≤ 0.03 to \> 4*Acinetobacter baumannii*--*A. calcoaceticus*\> 40.015 to \> 4\> 4≤ 0.12 to \> 4\>40.06 to \> 4*Burkholder cepacia*Ciprofloxacin susceptibleNR0.25NR1NR1Ciprofloxacin resistant160.25 to 16\> 1282 to \> 128\> 1282 to \> 128*Haemophilus influenza*0.004≤ 0.001 to 0.250.030.008 to \> 20.0150.004 to \> 2*Moraxella catarrhalis*0.0080.004 to 0.0150.060.03 to 0.120.060.015 to 0.06*Neisseria gonorrhea*0.060.125160.004 to \> 16*ESBL* extended-spectrum beta-lactamase, *MIC* minimum inhibitory concentration, *NA* not applicable, *NR* not reported

Among contemporary *S. aureus* isolates (MSSA and MRSA), delafloxacin MIC~50/90~ values were ≤ 0.004/0.25 mg/l, respectively \[[@CR18]--[@CR20]\]. For a number of bacterial species, including *S. aureus*, delafloxacin MICs were bimodal (0.002--0.003 and 0.06--4 mg/l), presumably because of existing fluoroquinolone resistance within the population \[[@CR20]\]. Applying the FDA *S. aureus* delafloxacin susceptibility MIC breakpoint of 0.25 mg/l to the cumulative MIC values from a diverse collection of contemporary isolates from US and European medical centers yields susceptibility rates of 98.7% and 88.0% for MSSA and MRSA, respectively \[[@CR6], [@CR19]\]. The corresponding levofloxacin susceptibility rates were 89.8% and 30%, respectively \[[@CR19]\].

McCurdy et al. recently evaluated the activity of delafloxacin against a global collection of *S. aureus* isolates (*n* = 687) from skin and skin structure infections, of which 34% demonstrated the levofloxacin-resistant phenotype \[[@CR18]\]. Among levofloxacin-susceptible strains, delafloxacin showed excellent in vitro activity, and MIC values were not affected by the methicillin-resistant phenotype (MIC~90~ 0.008 mg/l for both MSSA and MRSA). Delafloxacin maintained increased activity against levofloxacin-resistant MSSA and MRSA isolates; however, the MIC~90~ values were increased 32-fold (0.25 mg/l) compared with levofloxacin-susceptible strains \[[@CR18]\], which does raise questions pertaining to the risk of selecting resistant mutants during treatment, particularly in high inoculum *S. aureus* infections. Resistance selection studies have indeed demonstrated fewer passages are required to select mutants with increased MICs among fluoroquinolone-resistant *S. aureus* strains compared with sensitive strains \[[@CR20]\]. In the study by McCurdy et al., only three (0.4%) levofloxacin-resistant MRSA isolates had MIC values above the current delafloxacin *S. aureus* breakpoint \[[@CR18]\].

Delafloxacin also demonstrated potent activity against *S. pneumoniae*, and, similar to earlier respiratory fluoroquinolones, its activity extends to strains displaying penicillin-resistant or ceftriaxone non-susceptible phenotypes \[[@CR19]--[@CR22]\]. In a 2014 surveillance study, all European and 98% of US *S. pneumoniae* isolates were inhibited by delafloxacin ≤ 0.03 mg/l \[[@CR19]\]. These values are similar to those obtained in a bacterial respiratory surveillance program conducted 12 years earlier throughout Canada (CROSS), suggesting that delafloxacin, like other respiratory fluoroquinolones but in contrast to ciprofloxacin, has maintained its potency against *S. pneumoniae* despite the selective pressure of fluoroquinolone use during the intervening period \[[@CR21]\]. Approximately 1% of isolates in the US/European surveillance study displayed a levofloxacin-resistant phenotype (MIC \> 4 mg/l), and all were inhibited by delafloxacin ≤ 0.25 mg/l \[[@CR19]\].

Delafloxacin is also very active against gram-negative respiratory pathogens. *Haemophilus influenzae* and *Moraxella catarrhalis* MIC~90~ values were ≤ 0.004 and 0.008 mg/l, respectively \[[@CR22]\]. Due to the paucity of clinical data pertaining to outcomes with the use of delafloxacin for the treatment of respiratory tract infections at this time, the clinical breakpoints for these three pathogens have not yet been established.

The MIC~90~ value of contemporary *Enterococcus faecalis* isolates from both clinical and surveillance studies was 1 mg/l with a range of ≤ 0.004 to 2 mg/l (Table [1](#Tab1){ref-type="table"}) \[[@CR18]--[@CR20], [@CR23]\]. Among levofloxacin-resistant *E. faecalis* isolates, delafloxacin's MIC~50/90~ values were 0.25 and 8 mg/l, respectively \[[@CR23]\]. In the absence of clinical efficacy or PK/PD studies conducted with *E. faecalis*, the interpretive breakpoint of ≤ 0.12 mg/l was established by the FDA, which is many fold lower than the observed MIC~90~ values \[[@CR20]\]. As shown in Table [1](#Tab1){ref-type="table"}, delafloxacin is not expected to have useful activity against *E. faecium* (MIC~90~ \> 4 mg/l) \[[@CR19], [@CR20]\].

The in vitro activity of delafloxacin and fluoroquinolone comparators against a broad range of contemporary aerobic gram-negative bacteria is presented in Table [2](#Tab2){ref-type="table"}. As shown, delafloxacin MIC~90~ values for *E. coli* and *Klebsiella pneumoniae* exceed the clinical breakpoint of ≤ 0.25 mg/l by 16-fold and \> 16-fold, respectively \[[@CR19], [@CR20]\]. The levofloxacin-resistant phenotype was observed in approximately 30% and 20% of isolates, respectively, in these studies \[[@CR19], [@CR20]\]. In the surveillance study by Pfaller et al., delafloxacin susceptibility rates among US *E. coli* and *K. pneumoniae* isolates were 65% and 78%, respectively \[[@CR19]\]. Among isolates with the ESBL phenotype, susceptibility rates were just 17.3% and 5.7%, respectively \[[@CR19]\]. Against *Enterobacter* spp., delafloxacin appears less active than levofloxacin. Delafloxacin demonstrated more potent activity against *K. oxytoca* with MIC~90~ values of 0.12 mg/l \[[@CR19], [@CR20]\]. As shown in Table [2](#Tab2){ref-type="table"}, delafloxacin activity against *Pseudomonas aeruginosa* (MIC~50/90~ 0.25/4 mg/l; 65% susceptible) is similar to comparator anti-pseudomonal fluoroquinolones \[[@CR19], [@CR20]\].

Clinical experience with the indicated gram-negative pathogens has been very limited with most non-surveillance isolates cultured from poly-microbial infections in ABSSSI studies \[[@CR18], [@CR20]\]. If the use of delafloxacin is contemplated for infections in which gram-negative bacilli are common pathogens, additional clinical data are needed to better determine how MIC values measured by standard methods should inform treatment decisions.

Delafloxacin has shown excellent in vitro activity against *Neisseria gonorrheae* including ciprofloxacin-resistant and multidrug-resistant (MDR) strains (Table [2](#Tab2){ref-type="table"}) \[[@CR24]\]. Against a panel of *N. gonorrheae* clinical isolates collected from medical centers across the US during 2012 to 2015, including 67.5% with the ciprofloxacin-resistant phenotype, the delafloxacin MIC~90~ value was 0.125 mg/l \[[@CR24]\]. Lessons from the past however have shown that findings from in vitro studies may not be entirely predictive of clinical outcomes for *N. gonorrheae* infection \[[@CR25]\]. Unfortunately, a phase 3 trial comparing a single oral dose of delafloxacin (900 mg) to ceftriaxone for the treatment of uncomplicated gonorrhea (NCT02015637) was terminated early in 2015 for reasons of insufficient efficacy following an independent interim review \[[@CR26]\].

The in vitro activity of delafloxacin against *Mycobacterium tuberculosis* and *M. avium* was evaluated in a single study \[[@CR27]\]. Delafloxacin was more efficacious than levofloxacin at inhibiting intracellular macrophage growth of *M. tuberculosis*. It is hypothesized that this observation may be related to improved delivery of delafloxacin to the phagosomes of MM6-Mϕs that engulf bacteria. Additionally, the potentiation of delafloxacin's antimicrobial activity under the acidic conditions that are characteristic of the macrophage phagosomes that engulf mycobacterial pathogens may be particularly advantageous \[[@CR27]\]. Further support for delafloxacin's ability to accumulate and exert antibacterial activity within mammalian cells comes from demonstrations of its activity against *Chlamydia* spp., an obligate intracellular pathogen, with MICs ranging from 0.03 to 0.06 mg/l \[[@CR11]\].

Few studies have evaluated the activity of delafloxacin against clinically relevant anaerobic organisms \[[@CR11], [@CR28]\]. Potent activity was demonstrated against *Bacteroides fragilis* in particular in one study, with an MIC~90~ value of 0.125 mg/l \[[@CR28]\]. Caution is advised when interpreting the findings because isolates were collected nearly 15 years ago, and in the intervening period fluoroquinolone resistance among key anaerobic bacteria has increased significantly \[[@CR16], [@CR29]\]. More recent US surveillance data testing isolates collected during 2010 to 2012 have shown much lower susceptibility rates for moxifloxacin against key anaerobic species \[[@CR16], [@CR29]\]. Although the potential for cross-resistance among anaerobic species for delafloxacin and other fluoroquinolones has not been explored, high levels of cross-resistance have been documented between earlier fluoroquinolones.

More contemporary data pertaining to delafloxacin's activity against *Clostridium difficile* has been presented. Vernon et al. investigated the in vitro activity of delafloxacin and comparator agents against prevalent *C. difficile* ribotypes (RTs) \[[@CR30]\]. Delafloxacin's geometric mean (GM) MIC overall was 0.37 mg/l. Large differences in activity were observed for isolates belonging to the hypervirulent RT027 compared with non-RT027 (GM MIC 4.0, 0.13 mg/l, respectively), suggesting delafloxacin shares in the universal fluoroquinolone class resistance in this troublesome strain \[[@CR30]\].

Pharmacokinetics {#Sec6}
================

The PK properties of delafloxacin have been evaluated in phase 1 and 3 studies utilizing single and multiple ascending doses ranging from 300 to 1200 mg (IV) and 50 to 1600 mg (oral) \[[@CR31]--[@CR33]\]. As shown in Table [3](#Tab3){ref-type="table"}, at steady state, delafloxacin, administered as 300 mg IV every 12 h, achieves a maximum serum concentration (*C*~max~) of 9.29 mg/l and total exposure (AUC from 0 to 12 h, AUC~*τ*~) of 23.4 mg h/l. The bioavailability of the tablet formulation is 59%, which is lower than that of other fluoroquinolones such as levofloxacin and moxifloxacin (99% and 92%, respectively; Table [3](#Tab3){ref-type="table"}); however, the AUC~*τ*~ of delafloxacin 450 mg administered orally (20.6 mg h/l) is comparable to that achieved with a labeled IV dose of 300 mg \[[@CR6], [@CR32]--[@CR34]\]. Both the IV and oral formulations demonstrate approximate dose proportional increases in exposure following single doses ranging up to 1200 and 1600 mg, respectively \[[@CR32], [@CR33]\]. The *C*~max~ is reduced 20%, and the time to *C*~max~ (*T*~max~) is doubled when delafloxacin tablets are administered with food compared with the fasting state. However, total delafloxacin exposure (AUC~*τ*~) is similar when administered with or without food; thus, PK changes secondary to food intake around the time of dosing are not expected to affect clinical outcomes \[[@CR32], [@CR33]\].Table 3Pharmacokinetic parameters of delafloxacin and comparator fluoroquinolones.Adapted from references \[[@CR6], [@CR33]--[@CR35]\]ParameterDelafloxacin IV (300 mg, every 12 h)Delafloxacin PO (450 mg, every 12 h)Levofloxacin PO (750 mg, every 24 h)Ciprofloxacin PO (500 mg, every 12 h)Moxifloxacin PO (400 mg, every 12 h)*V*~d~ (l)35--4810084--189^a^119--189^a^*C*~max~ (mg/l)9.297.458.63.04.5*fC*~max~ (mg/l)1.491.195.3--6.51.8--2.42.25--3.15AUC~0--*τ*~ (mg h/l)30.823.490.713.748*f*AUC~0--*τ*~ (mg h/l)4.933.7456.2--68.98.2--11.024--33.6AUC~24~ (mg h/l)61.646.890.727.448*f*AUC~24~ (mg h/l)9.867.4856.2--68.916.4--22.024--33.6Protein binding84%24--38%20--40%30--50%*T*~1/2~ (h)3.7^b^4.2--8.58.84--610--14Elimination (urine:feces)64.5%:28.4%^b^50.2%:47.7%87%:4%57%:20--35%20%:25%Oral bioavailabilityN/A58.8%99%70%92%MetabolismGlucuronidation^c^Limited?Oxidation?Sulfation, glucuronidation*V*~*d*~ volume of distribution, *C*~*max*~ peak serum concentration, *fC*~*max*~ free peak concentration, *AUC*~*0--τ*~ area under the curve over the dosing interval, *fAUC*~*0-τ*~ free area under the curve over the dosing interval, *AUC*~*24*~ area under the curve over 24 h, *fAUC*~*24*~ free area under the curve over 24 h, *T*~*1/2*~ half- life^a^Based on a 70-kg adult^b^After a single dose^c^No significant circulating metabolites

Delafloxacin volumes of distribution have ranged from 35 to 48 l across studies. Protein binding (primarily to albumin) is approximately 84% (Table [3](#Tab3){ref-type="table"}) \[[@CR6], [@CR33]--[@CR35]\]. Delafloxacin shares the fluoroquinolone class characteristic of high pulmonary distribution with a 13:1 mean penetration ratio into the epithelial lining fluid vs. free plasma concentration \[[@CR36]\]. Data pertaining to the distribution characteristics of delafloxacin in other tissues have not been reported at this time.

Delafloxacin is primarily metabolized through glucuronidation, with oxidative metabolism accounting for approximately 1% of the administered dose, suggesting a low potential for drug interactions. The predominant route of elimination is renal (50--65%) with the remainder of elimination occurring in the feces as unchanged drug. Delafloxacin's half-life was 3.7 h following a single IV 300 mg dose and ranged from 4.2 to 8.5 h following multiple oral doses \[[@CR6], [@CR33], [@CR37]\].

PK parameters of delafloxacin have been examined in patients with varying degrees of renal impairment \[[@CR33]\]. Delafloxacin exposure has consistently been shown to increase with decreasing renal function; however, clinically important differences are not apparent until the estimated glomerular filtration rate (eGFR) as calculated using the Modification of Diet in Renal Disease equation (MDRD) is under 30 ml/min/1.73 m^2^. The AUC~*τ*~ increased 1.8-fold in patients with severe renal impairment (eGFR 15--29 ml/min/1.73 m^2^) following a single 300 mg IV dose. The corresponding fold changes in total exposure among patients with end-stage renal disease (ESRD) when delafloxacin was administered before and after hemodialysis (HD) were 2.1 and 2.6, respectively. Decreased plasma protein binding has also been observed in subjects with severe renal impairment and ESRD (80% and 75%, respectively). Based on population PK simulations, an adjusted dose of 200 mg IV every 12 h is recommended for patients with severe renal impairment \[[@CR6], [@CR33]\]. The lower dose also reduces the risk for adverse renal effects secondary to sulfobutylether-beta-cyclodextrin (SBECD, an excipient in the IV formulation) accumulation \[[@CR33]\].

Decreasing renal function does not appear to greatly impact the exposure of delafloxacin tablets; drug exposure was 1.5-fold higher in subjects with severe renal impairment following oral administration (450 mg) compared with subjects with normal renal function. A dosing regimen of 450 mg IV every 12 h produced exposures in patients with normal renal function similar to those achieved in patients with severe renal impairment that were administered the 450-mg oral dose, and tolerability was acceptable at these exposures \[[@CR33]\]. Thus, dosage adjustment of the oral formulation for patients with severe renal impairment is not recommended. Currently, there are no explicit labeled recommendations for dosing in patients maintained on HD. Twenty percent of the drug is removed during a 4-h HD session \[[@CR6]\].

The PK profile of delafloxacin has been evaluated in subjects with varying degrees of hepatic impairment. Total AUC values were similar in patients with normal, mild and moderate hepatic function. Higher PK variability was observed in patients with severe hepatic impairment, and total exposure was increased approximately 40% compared with controls. These differences are unlikely to be clinically important, and dosage adjustment in this population is not recommended \[[@CR33]\].

Pharmacodynamics {#Sec7}
================

Similar to other fluoroquinolones, delafloxacin exhibits concentration-dependent antimicrobial activity, and the unbound drug AUC over 24 h divided by the MIC of the pathogen (*f*AUC~24~/MIC) is the PK/PD parameter most closely associated with delafloxacin activity \[[@CR33], [@CR38]\]. The PD target value for delafloxacin against *S. aureus* was determined in a series of experiments using the murine neutropenic thigh infection model \[[@CR33]\]. Animals were inoculated with 10^6^ CFU of MSSA or MRSA possessing delafloxacin MICs ranging from 0.004 to 0.006 mg/l and 0.016 to 0.8 mg/l, respectively. Delafloxacin (1.25 to 320 mg/kg) was administered as a single dose, and the bacterial burden was determined 24 h after dosing. The median *f*AUC~24~/MIC ratios associated with net bacterial stasis and a 1-log~10~ CFU reduction were 9.3 and 14.3, respectively. Utilizing a murine lung infection model for collection of MSSA and MRSA isolates with MICs ranging from 0.004 to 0.008 mg/l, Andes et al. documented substantially lower median target ratios (stasis 1.74 and 1-log~10~ CFU reduction 7.92) \[[@CR39]\]. Similarly, the median *f*AUC~24~/MIC ratio of delafloxacin to achieve either stasis or 1-log~10~ CFU reduction in a neutropenic murine lung model by Thabit et al. utilizing MSSA isolates (MIC 0.002--0.52 mg/l) was 0.4 \[[@CR36]\]. However, the corresponding target ratios for MRSA isolates with baseline MICs of 0.25--1 mg/l were markedly higher in this study (stasis 8.1 and 1-log~10~ CFU reduction 24.7) and more closely aligned to those generally quoted for fluoroquinolones against gram-positive cocci (*f*AUC~24~/MIC ≥ 25) \[[@CR36], [@CR38]\]. Thus, it appears that PK/PD targets for delafloxacin may differ between stains, phenotypes and site of infection.

Similar experiments were also conducted to determine the threshold *f*AUC~24~/MIC ratios associated with efficacy against *E. coli* and *P. aeruginosa.* Findings indicated mean *f*AUC~24~/MIC targets for bacterial stasis and a 1-log~10~ CFU reduction for *E. coli* were 14.5 and 26.2, respectively, while the corresponding *f*AUC~24~/MIC targets for *P. aeruginosa* were 3.8 and 5.0, respectively.

*Staphylococcus aureus* is frequently associated with biofilm-related infections, which are particularly difficult to treat because antibiotics tend to be much less active against bacteria embedded in biofilm compared with those in the planktonic state \[[@CR40]\]. The increased potency of delafloxacin under acidic conditions may be particularly advantageous in this setting \[[@CR7]\]. Utilizing an in vitro PD model of mature *S. aureus* biofilms, Bauer et al. reported that delafloxacin reduced both MSSA and MRSA biofilm viability by at least 50% at clinically achievable concentrations \[[@CR41]\]. Delafloxacin, oxacillin (MSSA) and daptomycin were the most efficacious among a panel of nine anti-staphylococcal agents. The interpretation of these findings is somewhat hampered by the use of reference *S. aureus* strains displaying MICs that are 4- (MSSA) and 125-fold (MRSA) lower than MIC~90~ values documented in contemporary surveillance studies \[[@CR41]\].

In a second biofilm study using MSSA and MRSA with a broader range of delafloxacin MIC values (0.004--0.125 mg/l), delafloxacin displayed potent activity at clinically achievable concentrations against five of the seven isolates tested \[[@CR42]\]. Investigators did not account for delafloxacin protein binding (84%) when considering achievable *C*~max~ values in vivo however. The penetration of delafloxacin within the biofilm was observed to range from 0.62% to 51.8% and was generally greater in biofilms with lower pH values \[[@CR42]\].

Renal abscesses involving *S. aureus* are challenging to treat with currently available agents because of the presence of a large proportion of bacteria in the stationary phase of growth, and the local environment is usually characterized by low pH values \[[@CR7]\]. Ding et al. investigated the comparative activity of delafloxacin and moxifloxacin against renal abscesses formed by a community-associated MRSA strain (MW2) in a murine model of systemic infection \[[@CR43]\]. Both delafloxacin and moxifloxacin reduced the bacterial load in renal abscesses compared with controls. The reduction of the bacterial burden by delafloxacin was significantly greater than that by moxifloxacin \[[@CR43]\].

Delafloxacin has also demonstrated increased activity against gram-negative pathogens under acidic experimental conditions. So et al. examined the effect of urine matrix and its varying pH on the activity of delafloxacin and ciprofloxacin against 16 MDR urogenic *E. coli* and *K. pneumoniae* \[[@CR44]\]. All isolates were resistant to both ciprofloxacin (MIC 32 to \> 64 mg/l) and delafloxacin (MIC 2--16 mg/l) at baseline when measured in standard media. Similar to results obtained for delafloxacin against gram-positive pathogens tested under acidic experimental conditions \[[@CR7]\], delafloxacin MICs decreased by 1--3 doubling dilutions in 53% and 68% of observations for *E. coli* and *K. pneumoniae*, respectively, when MIC testing was performed in acidic urine. By contrast, MICs for ciprofloxacin remained relatively unchanged across the range of pH values tested \[[@CR7]\]. Even with the maximal MIC reductions when using urine as the test media, most isolates would continue to demonstrate MICs far above the current delafloxacin Enterobacteriaceae interpretive breakpoint of ≤ 0.25 mg/l; thus, the clinical implications of this study as relates to the potential utility of delafloxacin in the treatment of MDR Enterobacteriaceae are not entirely clear \[[@CR6], [@CR44]\].

Resistance {#Sec8}
==========

Resistance to fluoroquinolones most commonly involves step-wise chromosomal mutations in the quinolone resistance-determining regions (QRDR) of DNA gyrase (*gyr*A) and/or topoisomerase IV (*par*C/*grl*A). Overexpression of efflux pumps and decreased uptake secondary to reduced expression of outer membrane porins may also contribute to chromosomal resistance \[[@CR9], [@CR45]\]. Finally, plasmid-mediated fluoroquinolone resistance is an emerging concern \[[@CR45]\].

Delafloxacin maintains clinically useful activity against a range of bacteria displaying the quinolone-resistant phenotype secondary to single and double mutations in the QRDR as well as efflux pump expression. The ability of delafloxacin to select for spontaneous mutations within the QRDR or efflux pump gene loci in vitro has been investigated in a number of studies using both naïve strains and those with pre-existing mutations. Remy et al. conducted a series of spontaneous resistance selection experiments using four strains of *S. aureus*, three of which carried pre-existing mutations in the QRDR \[[@CR8]\]. The observed resistance frequencies were low (6.0 × 10^−9^ to \< 9.5 × 10^−9^) for delafloxacin at two times the baseline MIC and similar to those demonstrated for moxifloxacin \[[@CR8]\]. The resistance frequencies of both drugs were substantially less than that of levofloxacin. Notably, no delafloxacin-resistant strains could be isolated from the strain that had no pre-existing QRDR mutations \[[@CR6]\]. The minimum protective concentration in the present study ranged from one to four times the initial MIC for all quinolones tested. Delafloxacin-resistant mutants maintained their reduced susceptibility following passage in drug-free media for 7 days, suggesting a stable phenotype \[[@CR8], [@CR46]\].

Whole-genome sequencing characterized the nature of the mutations of the resultant variants. Delafloxacin-selected variants with MIC shifts ≤ 4-fold of the parent strain showed no genetic changes in the QRDR or the *nor*A loci, which encodes for the predominant fluoroquinolone efflux pump in *S. aureus*. Mutant strains with delafloxacin MICs ≥ 8-fold those of the parent strain were characterized by both previously described and novel mutations in *gry*A and *gyr*B. Two variant isolates, both with MICs of 4 mg/l and selected from a parent strain with pre-existing *gyr*A and g*rl*A mutations, showed no changes in the QRDR or the *nor*A sequence and its surrounding regulatory regions, suggesting delafloxacin resistance may arise through previously uncharacterized mechanisms \[[@CR8]\].

Clinical Efficacy {#Sec9}
=================

The clinical efficacy of delafloxacin has been evaluated in phase 2 and phase 3 studies among patients with ABSSSI as well as phase 2 studies among patients with acute exacerbation of chronic obstructive pulmonary disease and CAP \[[@CR47]--[@CR52]\].

The first clinical study to evaluate delafloxacin in the treatment of ABSSSIs was a phase 2 randomized, double-blind, multicenter, dose-ranging comparative study \[[@CR48]\]. Adults with wound infection, abscess or cellulitis were enrolled from 14 centers in the US; patients (*n* = 150) were randomized to delafloxacin 300 or 450 mg, each administered IV, every 12 h or tigecycline 100 mg IV once, followed by 50 mg IV, every 12 h for 5--14 days \[[@CR48]\]. *S. aureus* comprised nearly 90% of gram-positive pathogens, and methicillin-resistance was detected in 71%. Clinical cure rates and microbiologic eradication rates exceeded 90% in all treatment groups with no between-group differences.

Kingsley et al. performed the second phase 2 ABSSSI multicenter, randomized, double-blind trial evaluating delafloxacin (300 mg) versus linezolid (600 mg) and vancomycin (15 mg/kg, actual body weight; maximum 1250 mg; target trough 15--20 mg/l), each administered IV twice daily for 5--14 days \[[@CR47]\]. The addition of blinded aztreonam was permitted for patients with gram-negative infections randomized to linezolid or vancomycin. In total, 256 patients comprised the intention-to-treat population (ITT). *S. aureus* was the most frequently isolated organism with 67% of strains displaying the methicillin-resistant phenotype \[[@CR47]\]. Cure rates at the follow-up time point (day 14) were 70.4% in the delafloxacin group compared with 64.9% in the linezolid group (*P *= 0.496 vs. delafloxacin) and 54.1% in the vancomycin group (*P *= 0.031 vs. delafloxacin). The higher cure rate in the delafloxacin vs. vancomycin group appeared to be driven by patients with a body mass index (BMI) ≥ 30 kg/m^2^ (78.8% vs. 48.8%; *P* = 0.009). Among the microbiologically evaluable population (*n* = 125), presumed or documented eradication rates were similar between groups and ranged from 80.8% to 88.2% \[[@CR47]\].

There are several limitations to these studies that deserve comment. Importantly, as phase 2 trials, they were not designed with a formal pre-specified hypothesis or powered for any inferential statistical testing. Both trials included a relatively small number of patients and, as a consequence, the range of bacterial pathogens recovered was limited. Furthermore, patients most at risk for infection with a broader range of bacterial species (i.e., those who are immunocompromised or have severe underlying comorbidity) and who therefore may stand to benefit from delafloxacin's expanded spectrum of activity, were excluded from the studies. The MRSA MICs for delafloxacin were considerably lower than has been observed in recent surveillance studies \[[@CR20], [@CR47], [@CR48]\]. All patients were enrolled from US centers, which raises the question of whether the data are applicable across geographic populations. Finally, although most patients were treated in the outpatient setting, the efficacy of the oral formulation of delafloxacin was not evaluated.

To address these limitations as well as fulfill regulatory drug approval requirements, two phase 3 studies evaluating delafloxacin for the treatment of adult patients with ABSSSIs were initiated in 2013 (NCT01811732/RX-3341-302 and NCT1984684/RX-3341-303, hereafter referred to as study 302 and 303, respectively) \[[@CR51], [@CR52]\]. Both were multicenter, randomized, double-blind, non-inferiority studies comparing delafloxacin (300 mg) with vancomycin (15 mg/kg actual body weight) plus aztreonam (2 g), each administered IV, every 12 h for 5--14 days \[[@CR51], [@CR52]\]. In study 303, a switch to oral delafloxacin (450 mg) was mandated following six IV doses except for patients with an eGFR 15--29 ml/min who were to receive delafloxacin 200 mg IV every 12 h for all doses \[[@CR51], [@CR52]\]. If gram-negative pathogens were not isolated on the baseline culture, aztreonam was discontinued. No similar de-escalation to targeted therapy occurred for patients in the delafloxacin arms. Patients with infections involving prosthetic material or associated with human/animal bites, osteomyelitis, decubitus ulcer, diabetic foot ulcer, septic arthritis, necrotizing fasciitis or burns covering ≥ 10% of the body surface area were not eligible for enrollment. Other key exclusion criteria included severe underlying comorbidity (liver disease, end-stage renal disease, cardiac disease, malignancy), history of seizure disorder and pregnancy or lactation. The primary endpoint in the two studies was ≥ 20% reduction in lesion size at 48--72 h in the ITT population. In study 303, enrollment was expanded above the calculated sample size to enrich for a pre-specified subgroup analysis by BMI \[[@CR51], [@CR52]\].

In total, 660 and 850 patients were randomized in study 302 and 303, respectively. In both studies, the majority of patients were enrolled from US centers. The mean age of participants was approximately 46 and 50 years in study 302 and 303, respectively. Few patients aged 65 years and older were enrolled (7% and 20%, respectively). Approximately 80--90% of patients were Caucasian; African American patients were under-represented (7% and 20%). Obese patients (BMI ≥ 30 kg/m^2^) comprised 32% and 40% of the study populations. Eight to 13% of patients carried a diagnosis of diabetes, and approximately 1% had severely decreased renal function (eGFR \< 30 ml/min). Bacteremia was rare in both studies (2.3%, 2.2%) \[[@CR51], [@CR52]\].

The most prevalent pathogen isolated from the infection site was *S. aureus*, which was identified in 66% and 58% of the microbiologic ITT (MITT) patients in study 302 and 303, respectively. MRSA accounted for 52% and 36% of the *S. aureus* isolates, respectively \[[@CR51], [@CR52]\].

Delafloxacin was non-inferior to vancomycin plus aztreonam for the primary endpoint in both trials. Outcomes at the end of the therapy time point (14 ± 1 day) were similar, suggesting a sustained response to treatment in all groups. Importantly, outcomes at the later time points in study 303 are supportive of oral delafloxacin, which would have been initiated following assessment of the primary outcome. Among the MITT population, per pathogen response rates were generally similar between treatment groups across all pathogens. Overall, 66% of MRSA isolates were levofloxacin non-susceptible \[[@CR51]\]. Among these isolates, the delafloxacin MIC~90~ value was 0.25 mg/l, and the eradication or presumed eradication rate was 98.6%. One MRSA isolate displayed an MIC of 4 mg/l, and double mutations in both gyrA and parC were subsequently confirmed. The microbiologic response for the patient with this isolate was presumed eradicated based on clinical response. Approximately 15% of isolates recovered were gram-negative. The predominant gram-negative pathogens were *K. pneumoniae* and *E. coli*. Levofloxacin non-susceptibility was low among *K. pneumoniae* (2.2%), and most were susceptible to delafloxacin (MIC~50/90~ 0.12/0.25 mg/l). Levofloxacin non-susceptibility was slightly higher among *E. coli*, and the delafloxacin MIC~90~ was 4 mg/l \[[@CR51]\].

Subgroup analysis by age, sex, race and geographic region were consistent with the overall results; however, analysis is limited by the small number of patients in some subgroups, particularly those from regions outside of the US and African American patients \[[@CR51], [@CR52]\].

In study 302, an exploratory post hoc analysis by BMI category suggested a significant improvement in cure rates at the long-term follow-up time point among obese patients assigned to delafloxacin compared with vancomycin (71.7% vs. 57.5%; treatment difference 14.2%, 95% CI 1.3% to 26.9%) \[[@CR51], [@CR52]\]. This finding however was not subsequently confirmed in study 303, which, as noted previously, was enriched with obese patients to allow for formal statistical testing of this hypothesis. Among obese patients the cure rates at the late follow-up time point were similar (68.3% vs. 71.0%; treatment difference −2.7%, 95% CI − 11.5% to 6.0%). Information pertaining to vancomycin trough target attainment has not been reported for the overall study populations or by BMI category \[[@CR51], [@CR52]\].

Although these studies addressed several limitations of the phase 2 studies including a larger number of patients and conducting formal hypothesis testing, they did not expand knowledge of delafloxacin's performance among patients at risk for a broader range of pathogens. Key populations including the elderly, those with organ dysfunction, and those with significant underlying comorbidity were either excluded or under-represented. Furthermore, although too few gram-negative isolates were collected to allow for meaningful analysis, the high delafloxacin MIC values displayed among those that were obtained suggest delafloxacin may not be an ideal option when these pathogens are suspected, although, as noted previously, MIC values determined by standard methods may underestimate in vivo activity.

The efficacy of delafloxacin has also been explored among patients with respiratory tract infections \[[@CR49], [@CR50]\]. Longcor et al. conducted a phase 2, double-bind, randomized, dose-ranging study comparing three dose ranges of oral delafloxacin (100, 200, 400 mg daily ×  5 days) to levofloxacin (500 mg daily × 7 days) in adult outpatients diagnosed with ABECB \[[@CR49]\]. In total, 280 patients were randomized with a mean age of 61 years. Clinical cure rates were similar in the four groups (69--79%), and no dose-response trend was identified. Regarding bacteriologic cure rates, however, outcomes were improved among patients assigned to delafloxacin 400 mg compared with the lower doses. In the phase 2 study evaluating the clinical and bacteriologic outcomes with ascending delafloxacin doses (100, 200 or 400 mg once daily for 7 day) among adult outpatients with CAP (*n* = 309), clinical and bacteriologic cure rates were similar in the 200 and 400 mg groups and slightly lower for the 100 mg group \[[@CR50]\].

While the results of these studies are encouraging and appear to support a role for delafloxacin in the treatment of bacterial respiratory tract infections, further data from an ongoing phase 3 study comparing delafloxacin to moxifloxacin or linezolid for the treatment CAP (NCT02679573) are required before definitive conclusions pertaining to its efficacy for respiratory infections can be made.

Adverse Effects {#Sec10}
===============

For many years, fluoroquinolones were considered a safe and generally well-tolerated class of antimicrobials \[[@CR53]\]. In recent decades, however, safety concerns have led to restrictions on the use of fluoroquinolones and, in some instances, withdrawal of agents from the market \[[@CR53], [@CR54]\]. Recently, the FDA advisory committees on antimicrobial drugs and drug safety concluded that a risk vs. benefit analysis did not support the use of these agents in a number of uncomplicated infections, and labeling of all marketed fluoroquinolones has been updated to include stronger warnings pertaining to the risks serious adverse effects (AEs) such as tendon rupture, peripheral neuropathy and central nervous system (CNS) disturbances \[[@CR55]\]. Distinct differences among fluoroquinolones with regard to their safety profile can be predicted in part by structural differences with structure-AE relationships based on constituents at specific sites on the quinolone nucleus \[[@CR54]\]. Delafloxacin has a number of unique structural characteristics, however, which present challenges when attempting to predict the potential for serious AEs by this approach.

As with all fluoroquinolones, the most commonly reported AEs in phase 3 delafloxacin trials were gastrointestinal (GI) related (diarrhea 8%, nausea 8%) or mild CNS events \[[@CR56]\]. Data from phase 1 and 2 studies indicate an association between GI AEs and higher doses \[[@CR56]\]. There does not appear to be a clear fluoroquinolone structure-GI AE relationship, but rather GI AEs are thought to be due to direct GI irritation and/or indirect CNS effects \[[@CR53]\].

Tendinopathies are rare AEs associated with fluoroquinolones \[[@CR57]\]. Although there has not been a widely accepted structural moiety associated with tendinopathy, animal models suggest structural differences at position 7 may play a role with a methypiperadinyl group causing the highest number of tendon lesions \[[@CR57]\]. Delafloxacin is the only marketed fluoroquinolone with a weakly acidic substituent at this position \[[@CR58]\]. Three patients in pooled phase 3 delafloxacin trials reported tendonitis \[[@CR56]\]. One event was graded as moderate in severity, and all other events were considered to be mild. Predisposing factors such as concomitant steroid use and renal disease were not present in any of the affected patients \[[@CR56]\].

AEs involving the CNS have generally been the second most commonly encountered form of fluoroquinolone toxicity and include a broad variety of effects ranging from headaches and dizziness to acute psychosis to seizures \[[@CR54]\]. These effects are thought to occur secondary to fluoroquinolone blockade of GABA receptors \[[@CR53], [@CR54]\]. In vitro experiments suggest that the delafloxacin concentrations required to inhibit GABA are many fold above those achieved clinically \[[@CR56]\]. In line with these experimental observations, headache occurred in just 3% of delafloxacin-treated patients in pooled phase 3 trials, and other CNS AEs were relatively rare \[[@CR56]\]. No patients in the delafloxacin arms of phase 3 studies experienced seizures or convulsions \[[@CR56]\]. One patient who received a higher than labeled dose of delafloxacin (450 mg IV) during a phase 2 study experienced a seizure \[[@CR56]\].

Structural differences at positions 1, 5 and 8 of the quinolone nucleus influence the phototoxic potential \[[@CR54]\]. Fluoroquinolones with a halogen at position 8 of the nucleus along with a bulky side chain are well known for their associated phototoxicity \[[@CR53]\]. A methyl group at position 5 may also contribute \[[@CR53]\]. Delafloxacin contains a chlorine at position 8 but lacks a bulky side chain and contains no R5 substituent \[[@CR58]\]. A phase 1 study investigating the photosensitizing potential of delafloxacin demonstrated findings similar to placebo with no evidence of phototoxicity in either the low (200 mg) or high (400 mg) dose arms of delafloxacin-treated subjects \[[@CR56]\]. By comparison, more subjects assigned to the positive control group (lomefloxacin) exhibited both mild and severe phototoxicity at various wavelengths.

Assessment of the hepatotoxic potential of delafloxacin is limited by the relatively small number of patients who have been exposed at this time. Although case reports of severe liver injury emerged soon after trovafloxacin was introduced into the clinic, it was not until approximately 2.5 million courses of therapy had been administered that the causal relationship was deemed strong enough to warrant its removal from the market \[[@CR59]\]. The frequency of clinically significant elevations (\> 5 times the upper limit of normal) of aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase was 0.3% or less across delafloxacin groups in phase 3 trials, and no clinically significant elevations in bilirubin occurred \[[@CR56]\]. These parameters may be poorly predictive of the potential for drug-induced hepatotoxicity however.

The main area of interest relating to the cardiac toxicity of fluoroquinolones is prolongation of the QTc interval \[[@CR59]\]. The mechanism by which this occurs is likely multifactorial, and an obvious structural moiety that increases the risk for QTc prolongation has not yet been identified \[[@CR54]\]. Studies of various fluoroquinolones have shown a dose-dependent inhibition of the rapid-acting portion of the delayed rectifier potassium current, which is controlled by the human ether-a-go-go gene (HERG) \[[@CR60]\]. Preclinical studies with delafloxacin have found that it did not block HERG currents. In a phase 1 study delafloxacin doses up to three-fold higher than the currently labeled dose (900 mg) did not induce clinically meaningful changes in the QTc, while moxifloxacin, which served as the positive control, produced predicted prolongation of the QTc interval \[[@CR56], [@CR61]\]. In phase 3 studies, no occurrences of drug-induced arrhythmias were reported \[[@CR56]\].

Administration of fluoroquinolones has emerged as one of the most important risk factors for *C. difficile*-associated diarrhea (CDAD) caused by the hypervirulent RT027 strain \[[@CR62]\]. In early surveillance studies, delafloxacin demonstrated potent activity against many anaerobic species \[[@CR28]\]. In particular, it showed greater in vitro activity against *C. difficile* than comparator fluoroquinolones; however, activity against the RT027 strain was considerably lower \[[@CR30]\]. The impact of delafloxacin, of which 35--50% is eliminated unchanged in the feces, on bowel flora is unknown at this time. Two cases of CDAD were reported among patients enrolled in the delafloxacin arms of phase 2 and 3 studies \[[@CR56]\]. Both patients were noted to have a number of risk factors for CDAD besides antibiotic exposure \[[@CR56]\].

Fluoroquinolones are not known to commonly cause harmful effects on the kidneys; however, the vehicle used to deliver IV delafloxacin, SBECD, may be problematic in patients with renal impairment \[[@CR63]\]. A reduced delafloxacin dose (200 mg IV q12 h) is therefore recommended in patients with an eGFR \< 30 ml/min/1.73 m^2^ and a switch to oral delafloxacin as soon as clinically indicated \[[@CR6]\].

To summarize, the available data have not demonstrated significant safety concerns for delafloxacin. However, as with all new antibiotics, assessment of safety is limited by the small number of healthy subjects and patients to whom it has been administered. Exclusion criteria in completed phase 3 trials also limit the generalizability of safety findings to patients who may be more likely to receive this agent in the clinic, i.e., those with pre-existing organ dysfunction and a higher degree of baseline comorbidities. Nevertheless, the additional quasi-experimental data, which included positive controls for two important class AEs, phototoxicity and QTc prolongation, are reassuring.

Drug Interactions {#Sec11}
=================

Like other fluoroquinolones, delafloxacin forms insoluble chelation complexes with multivalent cations in the GI tract resulting in a substantial decrease in oral absorption of the antibiotic, and concomitant administration should be avoided \[[@CR6]\]. At clinically relevant concentrations, delafloxacin does not inhibit cytochrome P450 isoenzymes 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 or 3A4/5 \[[@CR56]\]. Delafloxacin demonstrated mild induction of CYP3A4 at clinically relevant concentrations in vitro; however, it did not affect the *C*~max~ and AUC values for midazolam (a sensitive CYP3A4 substrate) or its metabolite when administered to healthy volunteers prior to midazolam administration \[[@CR56]\]. Delafloxacin is a substrate of breast cancer-related protein (BCRP) and a potential substrate of P-glycoprotein \[[@CR56]\]. However, only modest increases in delafloxacin concentrations are anticipated when co-administered with BCRP or P-glycoprotein inhibitors, and the clinical significance is expected to be minimal \[[@CR56]\]. The impact of P-glycoprotein inducers, such as rifampicin, on delafloxacin exposure has not been reported.

Place in Therapy and Conclusions {#Sec12}
================================

ABSSSI is a popular market-entry indication for pharmaceutical companies developing new antimicrobials targeting MRSA \[[@CR64]--[@CR67]\]. Delafloxacin recently received FDA approval in this setting based on registry studies showing it to be an effective and well-tolerated alternative \[[@CR5]\]. Notable advantages of delafloxacin for the treatment of ABSSSI include the availability of both parenteral and oral formulations, a low potential for drug--drug interactions and reassuring clinical and experimental data pertaining to key class-adverse effects such as cardiotoxicity and phototoxicity. With the availability of a variety of new agents for the treatment of ABSSSI, it will be important to determine which agents are most suitable for specific patients on the basis of coverage (broad versus narrow spectrum), delivery (IV or PO) and potential for adverse reactions and compliance (single versus multiple daily dosing).

Of particular concern, fluoroquinolone use has been associated with increased rates of colonization and infection with MRSA, ESBL-producing Enterobacteriaceae and \[[@CR5], [@CR68]--[@CR70]\] the hypervirulent *C. difficile* RT027 strain \[[@CR62], [@CR70]\]. Recent international guidelines for the treatment of a number of infectious diseases explicitly recognize the ecologic AEs of fluoroquinolones as important factors in therapeutic decision-making and have called for more restricted use of these agents \[[@CR71], [@CR72]\]. As antibiotic innovation continues to move forward, greater attention needs to be placed on pinpointing unique properties of novel agents to assist in determining their specific therapeutic niche with respect to areas of unmet medical need while limiting collateral damage.

There are many important areas of unmet need in the treatment of gram-positive infections for which experimental data suggest the distinctive structural and chemical properties of delafloxacin may be harnessed to make it a particularly valuable addition to the antibiotic armamentarium. Improving long-term outcomes in patients with biofilm-associated infections is a critical unmet need, and delafloxacin's potent activity against *S. aureus* embedded in biofilm suggests a potential role in this setting \[[@CR41], [@CR42]\]. Antibiotics that are capable of eradicating intracellular non-replicating persister bacteria in bone, prosthetic device-associated infections and deep-seated abscesses are clearly an unmet medical need, and delafloxacin's excellent intracellular penetration, especially in the acidic conditions that are characteristic of these difficult to treat infections, points to another therapeutic niche \[[@CR7]\]. A potent oral agent would be particularly desirable in these settings because prolonged therapy with IV antibiotics is often necessary but associated with tremendous expense, inconvenience and harmful effects associated with extended catheterization. The prospect of combination therapy with delafloxacin and rifampicin for these infections is intriguing, and future research investigating the potential synergistic activity in biofilm models would be valuable. Delafloxacin's bactericidal activity and excellent pulmonary penetration \[[@CR36]\] are also suggestive of a promising role against pneumonia. The diminishing pool of effective antibiotics for gonorrhea represents an urgent public health threat \[[@CR73]\]. Although a single oral dose of delafloxacin was not sufficiently effective for uncomplicated gonorrhea infection, its potent in vitro activity against this pathogen \[[@CR24]\] suggests that evaluations of alternative dosing schedules would be worthwhile.

Struggles with resistance will not cease with the availability of new antibiotics, and we must learn how to optimally use and not abuse promising new agents such as delafloxacin. An oral antibiotic with in vitro activity against MRSA, *Pseudomonas* spp., anaerobes, and atypical organisms will attract many prescribers, and antimicrobial stewards will be tasked with implementing it appropriately into practice. As clinicians contemplate how to best incorporate delafloxacin into infectious disease treatment strategies, additional data pertaining to whether the promising experimental data detailed in this review do indeed translate into improved outcomes for patient with difficult to treat infections are greatly anticipated.
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